This small case study published in the Townsend Newsletter investigated the efficacy of Liposomal Nicotinamide Mononucleotide (NMN) on intracellular NAD+ levels and triglycerides in humans. The author is Dr. Alan Miller who is the science advisor for Cellg8, the manufacturer of the Liposomal NMN product tested.
- Increased Intracellular NAD+: Over a 15-day period, participants experienced a more than 100% increase in NAD+ levels.
- Triglyceride Reduction: Liposomal NMN supplementation demonstrated rapid triglyceride-lowering effects. After just five hours, participants experienced an average 15% decrease in triglycerides.
Standard NMN is poorly absorbed and when taken orally, it is quickly broken down in the stomach and small intestine due to stomach acid, bacteria, and enzymes. As a result, only a small percentage of NMN that is taken orally is actually absorbed into the bloodstream.
To address these concerns, a Liposomal powder preparation was used. Prior research has demonstrated the effectiveness of Liposomal preparations in enhancing the bioavailability and stability of molecules.
Case Study: Oral Supplementation with the NAD+ Precursor Nicotinamide Mononucleode (NMN)—Effects on Intracellular NAD+ and Triglycerides
The case study was comprised of 10 healthy participants, broken into two groups:
- Group 1: After a baseline triglyceride blood test, individuals were given a 1000 mg oral Liposomal NMN preparation (powder in a capsule) and underwent hourly triglyceride tests for five hours. Results indicated an average 15% decrease in triglycerides at the fifth hour compared to baseline.
- Group 2: Participants were tested for intracellular NAD+ levels (Jinfinity Labs) at baseline and then given a 1000 mg Liposomal powder NMN daily for 15 days. After the 15-day supplementation period, an intracellular NAD+ test was performed, revealing a remarkable 100% increase in NAD+ levels over this period.
Case Study Results
Rapid Reduction in Triglycerides
In the first group, participants had an average of 15% decrease in triglycerides at hour five, compared to baseline.
More than a 100% Increase in NAD+ Levels
In the second group, NAD+ levels increased from an average of 31.04 μM to 63.08 μM, an increase of more than 100% over the 15-day supplementation period, compared to baseline.
This is the first case series that has demonstrated a rapid triglyceride-lowering effect of oral
liposomal NMN (over 5 hours), along with a 2X increase in intracellular NAD+ over a 15-day period.
This study showed that oral administration of liposomal NMN rapidly reduced triglycerides in humans. Additionally, NAD+ levels increased more than 100% over the 15-day supplementation period, compared to baseline.
“This is the first case series that has demonstrated a rapid triglyceride-lowering effect of oral liposomal NMN (over 5 hours), along with a 2X increase in intracellular NAD+ over a 15-day period.”